Filing Details

Accession Number:
0001415889-24-028431
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-12-05 19:14:29
Reporting Period:
2024-12-03
Accepted Time:
2024-12-05 19:14:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1730430 Kiniksa Pharmaceuticals International Plc KNSA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1835458 Mark Ragosa
23 Old Bond Street, Third Floor
London X0 W1S 4PZ
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Ordinary Share Acquisiton 2024-12-03 8,969 $10.76 31,927 No 4 M Direct
Class A Ordinary Share Disposition 2024-12-03 8,969 $21.45 22,958 No 4 S Direct
Class A Ordinary Share Acquisiton 2024-12-04 5,024 $10.76 27,982 No 4 M Direct
Class A Ordinary Share Disposition 2024-12-04 5,024 $21.25 22,958 No 4 S Direct
Class A Ordinary Share Acquisiton 2024-12-05 1,123 $10.76 24,081 No 4 M Direct
Class A Ordinary Share Disposition 2024-12-05 1,123 $21.25 22,958 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Ordinary Share Share Option Disposition 2024-12-03 8,969 $0.00 8,969 $10.76
Class A Ordinary Share Share Option Disposition 2024-12-04 5,024 $0.00 5,024 $10.76
Class A Ordinary Shares Share Option Disposition 2024-12-05 1,123 $0.00 1,123 $10.76
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
33,081 2033-03-31 No 4 M Direct
28,057 2033-03-31 No 4 M Direct
26,934 2033-03-31 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.
  2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.26 and $21.70. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.265. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.265. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  5. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023.